

NUTRITION IN MEDICINE: CALORIES OR THERAPEUTIC MODALITY

AMERICAN COLLEGE OF OSTEOPATHIC INTERNISTS
CLINICAL CHALLENGES IN INPATIENT CARE

MATTHEW BECHTOLD MD, FACP, FACC, ACAF DIVISION OF CASTROENTEROLOGY UNIVERSITY OF MISSOURI - COLUMBIA

MARCH 25, 2017



DISCLOSURE

AMERICAN COLLEGE OF OSTEOPATHIC INTERNISTS NATIONAL MEETING

Nestle Nutrition Institute Speaker & Consultant

I will not discuss off label use or investigational use in my presentation



Matthew Bechtold MD bechtoldm@health.missouri.edu



QUESTIONS

How important is nutrition?

How do you assess nutrition needs?

Are there any nutrition therapies?

What is the future of nutrition?




Why is abbreviated such a long word?

Why is braille on drive-up ATMs?

Is there another word for synonym?

What happens when you get scared half-to-death twice?

BECHTOLD'S FOOD THE BACON PYRAMID





WHY ME?

- 1. I find nutrition fascinating
- 2. Nutrition deals with the gut and the gut is my thing
- 3. I have completed a nutrition fellowship
- 4. I am currently serving on 2 national ASPEN committees and 1 national task force for nutrition
- 5. I have published numerous articles and book chapters in nutrition



WEIGHT LOSS > 35%

†RISK OF DEATH

PROTEIN STORAGE LOSS > 30%

FAT STORAGE LOSS > 70%



CELIAC DISEASE

Gluten-Free Diet Folate, Fe, Fat-Soluble Vitamins Trace Minerals

CIRRHOSIS

Do Not Limit Protein
Watch For Hypoglycemia
Nutrition Improves Outcomes in Transplant

SHORT GUT SYNDROME

Maximize Nutrition Avoid Too Much CHO Ileal Adaptation

DUMPING SYNDROME

Frequent Small Meals
Avoid Simple CHO
Fluid Intake Separated From Meal

REFEEDING SYNDROME

Go Slow Watch Phosphorus

FOOD ALLERGIES

Just Say NO Supplements




EOPD

Meta-analysis
12 RCTs (n=448)
Stable COPD


| | | | | Change in handgrip strength |
|--------------------|----------------------|-------------------|---------|--------------------------------|
| Study name | Statistic | s for each s | tudy | Std diff in means |
| | Std diff in means | Standard error | p-value | and 95% CI |
| Efthimiou et al 13 | 1.071 | 0.572 | 0.061 | |
| Rogers et al 15 | 1.080 | 0.414 | 0.009 | |
| Weekes et al 25 | 0.148 | 0.271 | 0.586 | |
| Steiner et al 24 | 0.501 | 0.266 | 0.059 | |
| | 0.565 | 0.217 | 0.009 | |
| | | | | -3.0 -1.5 0 1.5 3.0 |
| | | | | Favours Favours |


Dietary advice (1)
or
Oral supplementation (10) vs Nothing
or
Enteral tube feeds (1)






NUTRITIONAL IMPACT **PANCREATITIS**





Meta-analysis 6 RCTs (n=326)

Predicted severe acute pancreatitis



 $EN \le 72$ hours vs TPN



NUTRITIONAL IMPACT PANCREATITIS

RCT (n=205)
19 Dutch Centers

| Outcome | Early Tube Feeding (N = 101) | On-Demand Tube Feeding (N = 104) | Risk Ratio (95% CI) | P Value |
|---|------------------------------------|--|------------------------|---------|
| Primary composite end point: infection or death — no. (%) | 30 (30) | 28 (27) | 1.07 (0.79–1.44) | 0.76 |
| Secondary end points | | | | |
| Infection — no. (%)† | 25 (25) | 27 (26) | 0.97 (0.70-1.34) | 0.87 |
| 1.6.1 | 0.70 | 75 (74) | 0.74 (0.42. 3.26) | 0.20 |

TYPE II STATISTICAL ERROR? LATE START OF EARLY GROUP FEEDING? SEVERITY SCALES ACCURATE?


| wechanical ventilation — no. (%) | 12 (12) | 14 (13) | 0.93 (0.60-1.44) | 0.84 |
|---|------------|------------|------------------|------|
| New-onset organ failure — no./total no. at risk (%)¶ | | | | |
| Single organ failure | 26/67 (39) | 31/73 (42) | 0.92 (0.65-1.32) | 0.73 |
| Persistent single organ failure | 10/67 (15) | 10/73 (14) | 1.05 (0.65-1.70) | 1.00 |
| Multiple organ failure | 7/67 (10) | 6/73 (8) | 1.14 (0.67-1.95) | 0.77 |
| Persistent multiple organ failure | 4/67 (6) | 4/73 (5) | 1.05 (0.51-2.14) | 1.00 |

Nasoenteric tube feeds ≤ 24 hours vs Oral Diet/tube feeds @ 72 hours



Meta-analysis 7 RCTs (n=352)

INDUCING REMISSION IN CROHN'S DISEASE Enteral Nutrition vs Steroids





IBD

Meta-analysis 5 RCTs (n=403)

INDUCING AND SUSTAINING REMISSION IN CROHN'S DISEASE

| | Favors ED + Infliximab | | Favors Infliximab Alone | | Odds Ratio | | Odds Ratio |
|-----------------------------|------------------------|-------|-------------------------|-------|------------|--------------------|---|
| Study or Subgroup | Events | Total | Events | Total | Weight | M-H, Fixed, 95% CI | M-H, Fixed, 95% CI |
| Hirai et al - 2012 | 31 | 45 | 24 | 57 | 24.4% | 3.04 [1.34, 6.92] | |
| Matsumoto et al - 2005 | 15 | 49 | 4 | 12 | 16.5% | 0.88 [0.23, 3.39] | |
| Sazuka et al - 2012 | 23 | 29 | 22 | 45 | 13.2% | 4.01 [1.37, 11.71] | |
| Tanaka et al - 2006 | 30 | 51 | 22 | 59 | 31.1% | 2.40 [1.11, 5.18] | |
| Yamamoto et al - 2009 | 25 | 32 | 16 | 24 | 14.8% | 1.79 [0.54, 5.89] | |
| Total (95% CI) | | 206 | | 197 | 100.0% | 2.43 [1.58, 3.74] | • |
| Total events | 124 | | 88 | | | | |
| Heterogeneity: Chi*= 3.50 | 6, df = 4 (P = 0.47) | P= 0% | | | | | |
| Test for overall effect; Z= | | | INDUCTI | ON C | FRE | MISSION | 0.01 0.1 1 10 100 Favors Infliximab Alone Favors EN + Infliximab |
| | | | | | | | Favors initizimas Alone Favors EN + Initizimas |

| | Favors EN + Infli | ximab | Favors Inflixima | b Alone | | Odds Ratio | Odds Ratio |
|---------------------------------------|----------------------|-----------|------------------|---------|--------------|--------------------|---|
| Study or Subgroup | Events | Total | Events | Total | Weight | M-H, Fixed, 95% CI | M-H, Fixed, 95% CI |
| Hirai et al - 2012 | 31 | 45 | 24 | 57 | 46.5% | 3.04 [1.34, 6.92] | |
| Sazuka et al - 2012 | 23 | 29 | 22 | 45 | 25.2% | 4.01 [1.37, 11.71] | _ - |
| Yamamoto et al - 2009 | 25 | 32 | 16 | 24 | 28.3% | 1.79 [0.54, 5.89] | |
| Total (95% CI) | | 106 | | 126 | 100.0% | 2.93 [1.66, 5.17] | • |
| Total events | 79 | | 62 | | | | |
| Heterogeneity: Chi ² = 1.0 | 0, df = 2 (P = 0.61) | ; I² = 0% | | | | | 100 |
| Test for overall effect: Z = | 3.71 (P = 0.0002) | | REMI | SSIO | N > 1 | YEAR | 0.01 0.1 1 10 100 Favors Infliximab Alone Favors EN + Infliximab |


Enteral nutrition therapy (elemental or polymeric formula, with or without low-fat diet restriction) with infliximab

VS

Infliximab alone with no dietary manipulation



"NUTRITIONAL IMPACT COLORECTAL CANCER




INCREASE RISK

Red Meat **Processed Meat** Highly Refined Grains and Starches Sugars



NUTRITIONAL IMPACT EOLORECTAL CANCER



Meta-analysis 12 Prospective Cohort Studies (n=1,170,942)

FUTURE IMPACT

Vitamin D Fiber Folic Acid Magnesium



NUTRITIONAL ASSESSMENT

MEDICAL HISTORY

Nutritional deficiencies

in diet

Eating habits

Food diary

Dieting???

PHYSICAL EXAM

BMI

Ideal body weight (IBW)

Present body weight (PBW)

Deviation from average body weight over past 3-6 months



NUTRITIONAL ASSESSMENT

ANTHROPOMORPHIC MEASUREMENTS HAND-HELD CALIPERS BODY MASS INDEX

BIOCHEMICAL MEASUREMENTS

ALBUMIN
PREALBUMIN
TRANSFERRIN
CREATININE

IMMUNOLOGIC MEASUREMENTS LYMPHOCYTE COUNT



NUTRITIONAL ASSESSMENT

• BMI = Weight (kg) / Height (m) 2

| BMI TABLE | Caucasians | Asians |
|----------------|------------|-----------|
| Normal | < 25 | < 23 |
| Overweight | 25 - 29.9 | 23 - 29.9 |
| Obese | 30 – 39.9 | 30 – 39.9 |
| Severe Obesity | ≥ 40 | ≥ 40 |

• Problems:

– Muscle mass does not count:

Terrell Owens BMI = $6^{\circ}3^{\circ}$ and 224 lbs = 28

Dwayne Johnson (AKA The Rock) BMI = 6'5" and 260 lbs = 31



NUTRITIONAL ASSESSMENT GLOBAL ASSESSMENTS

NO SINGLE TOOL IS AN ACCURATE PREDICTOR OF NUTRITIONAL STATUS

Heat produced by oxidation

Resting energy expenditure: Measured by ventilated hood over pt's head x 2 hrs $(O_2 \text{ and } CO_2 \text{ content})$

Subjective Global Assessment



SUBJECTIVE GLOGAL ASSESSMENT

| (Select an appropriate category with a checkmark, or enter numerical value where indicated by "#") |
|--|
| A. History 1. Weight change Overall loss in past 6 months: amount = # kg; percent loss = # Change in past 2 weeks: increase, no change, decrease. |
| 2. Dietary intake change (relative to normal) |
| Gastrointestinal symptoms (that persisted for >2 weeks) none, nausea, vomiting, diarrhea, anorexia. |
| 4. Functional capacity ————— No dysfunction (eg, full capacity), ——————————————————————————————————— |
| Disease and its relation to nutritional requirements Primary diagnosis (specify): |
| Metabolic demand (stress): no stress, low stress, high stress. |
| B. Physical (for each trait specify: 0 = normal, 1+ = mild, 2+ = moderate, 3+ = severe). # |
| C. SGA rating (select one) A = Well nourished B = Moderately (or suspected of being) malnourished C = Severely malnourished |



FEEDING

METHODS

ENTERAL FEEDING

By Mouth Tube Feeding

PARENTERAL FEEDING

Total Parenteral Nutrition
Peripheral Parenteral Nutrition

WHICH ONE?

"If the gut works, use it!"

- Stevan Whitt MD





BENEFIT

Strokes
Head & Neck Cancers
Life-Expectancy > Few Months

MAY NOT BENEFIT

Alzheimer's Dementia

Roth. Biomedical Ethics Seminar 2007 Finucane, et al. J Am Med Dir Assoc 2007 Finucane, et al. JAMA 1999 Cervo, et al. Geriatrics 2006 Roth, et al. Stroke 2002



PEGs

REALITY OF PEG TUBES

Nutritional status does not necessarily improve


Diarrhea, clogging of tube, pulling out of tube Increased nutrients do not necessarily result in meaningful clinical outcomes

Continued risk of aspiration
Survival rates same for PEG and spoon fed patients
Mortality rates

2% to 27% at 30 days and 50% or more at 1 year

Restraints often required leading to discomfort and compromised autonomy
Denied pleasure of eating
Adverse effects with feeding tube due to complications





Roth. Biomedical Ethics Seminar 2007 Finucane, et al. J Am Med Dir Assoc 2007 Finucane, et al. JAMA 1999 Cervo, et al. Geriatrics 2006 Roth, et al. Stroke 2002



PEG COMPLICATIONS

Major Complications

Necrotizing Soft

Tissue Infection

Buried Bumper

Syndrome

Colocutaneous

Fistula

Inadvertent PEG

Removal

Minor Complications

Wound Infection

Peristomal Leakage

Pneumoperitoneum

Ileus

Bleeding

Ulceration

Clogging

Tube Dysfunction


Gastric Outlet Obstruction



| | % |
|---|-------------------------|
| PEG tubes performed per month | |
| 1–5 | 64.3 |
| 6–10 | 32.1 |
| >11 | 3.6 |
| Awareness of recent literature regard feeding after PEG tube | ding early |
| Aware | 81.5 |
| Unaware | 18.5 |
| Respondents timing of initiation of f | feedings after PEG tube |
| <3 hr | 10.7 |
| 4–8 hr | 28.6 |
| 9–15 hr | 17.9 |
| 16–24 hr | 39.3 |
| >24 hr | 3.5 |



Complications:




• Death ≤ 72 hours:

| | Early Feeding Delayed Feeding | | Odds Ratio | | Odds Ratio | | |
|---|-------------------------------|-------|------------|-------|------------|--------------------|--|
| Study or Subgroup | Events | Total | Events | Total | Weight | M-H, Fixed, 95% CI | M-H, Fixed, 95% CI |
| Choudhry et al | 0 | 21 | 1 | 20 | 21.2% | 0.30 [0.01, 7.87] | - |
| Schulte-Bockholt et al | 2 | 37 | 3 | 40 | 38.5% | 0.70 [0.11, 4.47] | |
| Stein et al | 2 | 40 | 3 | 40 | 40.3% | 0.65 [0.10, 4.11] | |
| Total (95% CI) | | 98 | | 100 | 100.0% | 0.60 [0.18, 1.99] | |
| Total events | 4 | | 7 | | | | |
| Heterogeneity: Chi ² = 0.21, df = 2 (P = 0.90); I^2 = 0% Test for overall effect: Z = 0.84 (P = 0.40) | | | | | | | 0.01 0.1 1 10 100 Favors Early Feeding Favors Delayed Feeding |

Residuals during first 24 hours:

| | Early Fee | eding | Delayed Fe | eding | Odds Ratio | | Odds Ratio |
|--------------------------------------|---------------|----------|-------------|-------|------------|--------------------|--|
| Study or Subgroup | Events | Total | Events | Total | Weight | M-H, Fixed, 95% CI | M-H, Fixed, 95% CI |
| Choudhry et al | 2 | 21 | 1 | 20 | 6.4% | 2.00 [0.17, 23.96] | |
| Chumley et al | 13 | 40 | 11 | 40 | 51.4% | 1.27 [0.49, 3.31] | · · · · · · · · · · · · · · · · · · · |
| Schulte-Bockholt et al | 1 | 50 | 0 | 50 | 3.4% | 3.06 [0.12, 76.95] | |
| Stein et al | 10 | 37 | 8 | 40 | 38.8% | 1.48 [0.51, 4.28] | - |
| Total (95% CI) | | 148 | | 150 | 100.0% | 1.46 [0.75, 2.84] | • |
| Total events | 26 | | 20 | | | | |
| Heterogeneity: Chi ² = 0. | .35, df = 3 (| P = 0.99 | 5); I² = 0% | | | | |
| Test for overall effect: Z | = 1.11 (P = | 0.27) | | | | | 0.01 0.1 1 10 100 Favors Early Feeding Favors Delayed Feeding |







444 PEGs

June 2006 – December 2011

| PARAMETER | EARLY FEEDING (≤ 4 HOURS) | DELAYED FEEDING (> 4 HOURS) | P-VALUE | | | | | | |
|-----------------|------------------------------|--------------------------------|---------|--|--|--|--|--|--|
| | MORTALITY | | | | | | | | |
| < 24 hours | 0 | 0 | NS | | | | | | |
| 24-72 hours | 2 | 0 | 0.20 | | | | | | |
| 3-30 days | 14 | 19 | 0.86 | | | | | | |
| | COMPLICATIONS | | | | | | | | |
| Wound Infection | 5 | 4 | 0.52 | | | | | | |
| Melena | 0 | 3 | 0.26 | | | | | | |
| Vomiting | 9 | 16 | 0.42 | | | | | | |
| Leakage | 4 | 2 | 0.41 | | | | | | |
| Stomatitis | 0 | 4 | 0.13 | | | | | | |
| Other | 27 | 28 | 0.47 | | | | | | |



SHORT GUT SYNDROME

ELDERLY


EATING DISORDERS

OBESITY

ICU




OBESITY






OBESITY





OBESITY






CRITICAL CARE

CHANGING PARADIGM: NUTRITION SUPPORT TO NUTRITION THERAPY

OLD SCHOOL



"Skeletons in the Closet"
PEM in 50% pts US hospitals
Support to prevent PEM
PN-based, little effect



Maintain gut integrity Immune-modulation Down-regulate inflammation EN-based, huge effect



PERSPECTIVE ON ENTERAL FEEDING, OXIDATIVE STRESS, AND PHARMACONUTRITION





CRITICAL CARE NUTRITION

GUT DOES MORE THAN CALORIES

NUTRITION IN CRITICAL CARES CALORIES OR THERAPEUTIC MODALITY

THE ROLE OF IMMUNONUTRITION

CONTROVERSY OF IMMUNE FORMULAS

